Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$1.55
+2.0%
$1.66
$1.10
$4.10
$57.20M-0.9512,148 shs891 shs
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
$0.78
-2.6%
$2.88
$0.69
$29.40
$5.30M1.27747,056 shs520,387 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$2.13
-3.6%
$1.82
$1.12
$8.40
$63.57M-0.9870,232 shs1.25 million shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$16.14
-3.8%
$16.90
$12.12
$26.99
$51.55M0.5822,447 shs241 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
0.00%+0.66%+3.40%-21.65%-55.29%
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
+0.59%-60.25%-73.76%-84.99%-93.22%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-3.07%+88.89%+25.57%-15.00%-41.07%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-1.31%-0.95%+6.40%-16.79%-18.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
1.3973 of 5 stars
3.05.00.00.00.00.00.0
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
1.4598 of 5 stars
3.52.00.00.00.60.00.6
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
2.9039 of 5 stars
3.83.00.00.01.90.00.6
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.5767 of 5 stars
3.52.00.00.02.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
2.00
Hold$9.00480.65% Upside
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
3.00
Buy$32.003,992.07% Upside
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
3.50
Strong Buy$15.00604.23% Upside
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50120.02% Upside

Current Analyst Ratings Breakdown

Latest BCTX, TELO, VTVT, and ANL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/22/2025
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$5M11.44N/AN/A$0.69 per share2.25
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
N/AN/AN/AN/A($2.20) per shareN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$17K3,032.43N/AN/A$4.48 per share3.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
-$51.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$16.53M-$0.42N/AN/AN/AN/A-2,009.40%-1,009.72%8/12/2025 (Estimated)
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$18.46M-$3.01N/AN/AN/A-121.46%-46.75%8/6/2025 (Estimated)

Latest BCTX, TELO, VTVT, and ANL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.85N/AN/AN/AN/AN/A
8/12/2025N/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.08N/AN/AN/AN/AN/A
6/13/2025Q3 2025
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
-$1.76-$1.64+$0.12-$1.64N/AN/A
5/15/2025Q1 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.73-$0.77-$0.04-$0.77N/AN/A
5/12/2025Q1 2025
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
N/AN/AN/AN/AN/A
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
N/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
0.02
1.41
1.41
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
N/A
3.41
3.41
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
0.75
0.75
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
7.39
7.39

Institutional Ownership

CompanyInstitutional Ownership
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
35.21%
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
15.42%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
N/A
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
5.73%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
12736.90 millionN/ANot Optionable
BRIACELL THERAP stock logo
BCTX
BRIACELL THERAP
86.78 million6.39 millionNo Data
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
129.76 millionN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.20 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
vTv Therapeutics stock surges on FDA update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adlai Nortye stock logo

Adlai Nortye NASDAQ:ANL

$1.55 +0.03 (+1.97%)
As of 11:08 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

BRIACELL THERAP stock logo

BRIACELL THERAP NASDAQ:BCTX

$0.78 -0.02 (-2.62%)
As of 02:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Telomir Pharmaceuticals stock logo

Telomir Pharmaceuticals NASDAQ:TELO

$2.13 -0.08 (-3.62%)
As of 02:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$16.14 -0.64 (-3.79%)
As of 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.